Home › Compare › TYPFF vs ABBV
TYPFF yields 1333.33% · ABBV yields 3.06%● Live data
📍 TYPFF pulled ahead of the other in Year 1
Combined, TYPFF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TYPFF + ABBV for your $10,000?
Goldflare Exploration Inc. acquires, explores for, and develops gold properties in Canada. The company holds 100% interests in the Aiguebelle-Goldfields property consisting of 6 mining claims and covering an area of 253.85 hectares located in the Abitibi-Temiscamingue region; the Syenite Condor property consisting of 20 mining claims and covering an area of 653.12 hectares located in the Clericy Township; the Ranger property consisting of 39 mining claims and covering an area of 1,052.47 hectares located in the Clericy Township; the Windfall property consisting of 28 mining claims and covering an area of 1,145.62 hectares located in the Belmont Township; the Duplessis-Agar property consisting of 10 mining claims and covering an area of approximately 560 hectares located in the Duplessis region; and Duplessis-Mountain property consisting of 6 mining claims and covering an area of approximately 340 hectares located in the Urban-Barry mining camp. It holds 50% interest in the Destorbelle property consisting of 24 mining claims and covering an area of 950.47 hectares located in the Aiguebelle and Destor townships. The company was formerly known as Typhoon Exploration Inc. and changed its name to Goldflare Exploration Inc. in September 2021. Goldflare Exploration Inc. was founded in 2003 and is headquartered in Piedmont, Canada.
Full TYPFF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.